Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $8.6 million.

  • Viking Therapeutics' Share-based Compensation rose 5152.64% to $8.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $40.8 million, marking a year-over-year increase of 3737.88%. This contributed to the annual value of $40.8 million for FY2025, which is 3737.88% up from last year.
  • Viking Therapeutics' Share-based Compensation amounted to $8.6 million in Q4 2025, which was up 5152.64% from $7.3 million recorded in Q3 2025.
  • In the past 5 years, Viking Therapeutics' Share-based Compensation registered a high of $13.5 million during Q2 2025, and its lowest value of $1.4 million during Q4 2021.
  • In the last 5 years, Viking Therapeutics' Share-based Compensation had a median value of $4.3 million in 2023 and averaged $5.1 million.
  • Per our database at Business Quant, Viking Therapeutics' Share-based Compensation surged by 13097.94% in 2023 and then tumbled by 1832.55% in 2025.
  • Quarter analysis of 5 years shows Viking Therapeutics' Share-based Compensation stood at $1.4 million in 2021, then soared by 50.45% to $2.2 million in 2022, then skyrocketed by 89.24% to $4.1 million in 2023, then surged by 38.9% to $5.7 million in 2024, then surged by 51.53% to $8.6 million in 2025.
  • Its Share-based Compensation stands at $8.6 million for Q4 2025, versus $7.3 million for Q3 2025 and $13.5 million for Q2 2025.